Document Detail

Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
MedLine Citation:
PMID:  23275304     Owner:  NLM     Status:  In-Data-Review    
Absence of, or loss-of-function mutations in the dysferlin gene (dysf) result in dysferlinopathy, characterized by increased muscle inflammation, collagen deposition and deterioration in muscle function. We evaluated halofuginone efficacy in improving muscle histopathology in mice with deleted dysf transmembrane domain. Quadriceps sublumbar and longissimus muscles of 9-month-old dysf-/- mice treated with halofuginone for 4 months exhibited a reduction in centrally-nucleated myofibers, inflammatory infiltrates and collagen content. Late onset of dysferlinopathy makes it ideal for evaluating the efficacy of early treatments on late outcome. The dysf-/- mice were treated with halofuginone for 3 to 4 months starting at 1, 5 or 9 months of age, and quadricep muscle histopathology was evaluated at 12 months. Collagen content and number of centrally nucleated myofibers decreased after early halofuginone treatment, administered when myofibers with central nuclei and inflammatory infiltrates are evident, but there was almost no fibrosis. When administered at the beginning of fibrosis it resulted in a further decrease in the number of centrally-nucleated myofibers with no additional decrease in collagen levels. Cardiac fibrosis was almost completely abolished following early halofuginone treatment. Halofuginone inhibited Smad3 phosphorylation and its translocation to the nucleus and increased the activity of matrix metalloproteinases 9 and 2 responsible for resolution of pre-existing collagen. Macrophage and myofibroblast invasion into the dystrophic muscle at the site of myofibers with central nuclei was inhibited by halofuginone. These results suggest that early halofuginone treatment can prevent the late outcome of dysferlinopathy and can cause resolution of the established fibrosis when administered at later stages.
O Halevy; O Genin; H Barzilai-Tutsch; Y Pima; O Levi; I Moshe; M Pines
Related Documents :
24042504 - Altered skeletal muscle mitochondrial biogenesis but improved endurance capacity in tra...
23226244 - Camp/protein kinase a activates cystic fibrosis transmembrane conductance regulator for...
23846614 - Skeletal muscle abnormalities and exercise capacity in adults with a fontan circulation.
25454684 - Altered ventral neck muscle deformation for individuals with whiplash associated disord...
22898554 - Elastic recoil can either amplify or attenuate muscle-tendon power, depending on inerti...
1806844 - Enzyme-histochemical study on the fine distribution of the intramural lymphatics at the...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Histology and histopathology     Volume:  28     ISSN:  1699-5848     ISO Abbreviation:  Histol. Histopathol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2012-12-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8609357     Medline TA:  Histol Histopathol     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  211-26     Citation Subset:  IM    
Department of Animal Sciences, the Hebrew University of Jerusalem, Rehovot, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pulmonary toxicity of instilled cadmium-doped silica nanoparticles during acute and subacute stages ...
Next Document:  Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer.